PROVECTUS BIOPHARMACEUTICALS, INC.
For the period ended Jun 30, 2026. Filed Aug 13, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 13, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 1A. Risk Factors
The following risk factor is provided as an update to our previously disclosed risk factors:
Changes in U.S. Trade Policies and Other Geopolitical Events Could Adversely Affect Our Operations
Ongoing uncertainty around U.S. trade policies, tariffs, and international agreements may impact the cost and availability of materials, supplies, and equipment used in the Company’s operations or those of the Company’s partners. Any disruptions or increased costs resulting from these changes could negatively affect the Company’s business, financial condition, results of operations, and the market price of the Company’s common stock.
In addition, ongoing international conflicts (including military conflicts between Russia and Ukraine and in the Middle East) have created volatility in the global capital markets and may have further global economic consequences, including disruptions of the supply chain. Any such volatility and disruptions may adversely affect our business or the third parties on whom we rely.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.